Recurrence of a high-titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis

被引：8
|
作者：
Doshi, Bhavya S. [1 ,2 ]
Witmer, Char M. [1 ,2 ]
机构：
[1] Childrens Hosp Philadelphia, Div Hematol, 3501 Civ Ctr Blvd,CTRB 5024, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA
来源：
HAEMOPHILIA | 2021年 / 27卷 / 04期
关键词：
emicizumab; haemophilia A; immune tolerance; inhibitor; recurrence; IMMUNE TOLERANCE;
D O I：
10.1111/hae.14311
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E551 / E553
页数：3
相关论文
共 50 条
  • [21] Daratumumab rapidly reduces high-titre factor VIII inhibitors in haemophilia A patients during life-threatening haemorrhages
    Moonla, Chatphatai
    Uaprasert, Noppacharn
    Watanaboonyongcharoen, Phandee
    Meesanun, Mukmanee
    Sukperm, Autcharaporn
    Jantasing, Ratchaneekorn
    Faknuam, Saruta
    Chanswangphuwana, Chantiya
    Polprasert, Chantana
    Sodsai, Pimpayao
    Akkawat, Benjaporn
    Hirankarn, Nattiya
    Bunworasate, Udomsak
    Rojnuckarin, Ponlapat
    HAEMOPHILIA, 2021, 27 (01) : E155 - E159
  • [22] Moyamoya syndrome in a hemophilia A patient with a high-titre FVIII inhibitor
    Hassenpflug, W. A.
    Schrum, J.
    Albisetti, M.
    Khan, N.
    Schneppenheim, R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 325 - 325
  • [23] Immune Tolerance Induction (ITI) in Paediatric and Adult Patients with Haemophilia a (HA) and High-Titre (HT) Factor VIII (FVIII) Inhibitor - Real Life Data
    Letowska, Magdalena Katarzyna
    Zawilska, Krystyna
    Klukowska, Anna
    Chojnowski, Krzysztof
    Zdziarska, Joanna
    Stefanska-Windyga, Ewa
    Windyga, Jerzy
    BLOOD, 2019, 134
  • [24] Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titre inhibitor
    Montoro, JB
    Altisent, C
    Pico, M
    Cabanas, MJ
    Vila, M
    Puig, LL
    HAEMOPHILIA, 1998, 4 (05) : 762 - 765
  • [25] Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures
    Cooper, HA
    Jones, CP
    Campion, E
    Roberts, HR
    Hedner, U
    HAEMOPHILIA, 2001, 7 (05) : 517 - 522
  • [26] The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile
    Greninger, D. A.
    Saint-Remy, J. M.
    Jacquemin, M.
    Benhida, A.
    Dimichele, D. M.
    HAEMOPHILIA, 2008, 14 (02) : 295 - 302
  • [27] Effective and safe use of recombinant factor VIIa (NovoSeven®) in elderly mild haemophilia A patients with high-titre antibodies against factor VIII
    Leebeek, FWG
    Kappers-Klunne, MC
    Jie, KSG
    HAEMOPHILIA, 2004, 10 (03) : 250 - 253
  • [28] Rapid immune tolerance induction following primary immunologic prophylaxis in a hemophilia A patient with high-titre inhibitor
    Moorehead, P. C.
    Thibeault, L.
    Tuttle, A.
    Grabell, J.
    Dwyre, L.
    Silva, M.
    James, P.
    Lillicrap, D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 1077 - 1078
  • [29] Safety and efficacy of recombinant activated factor VII for long-term secondary prophylaxis in a haemophilia boy with high-titre inhibitors
    Chuansumrit, A.
    Sirachainan, N.
    Panuwannakorn, M.
    Wongwerawattanakoon, P.
    Kadegasem, P.
    Choeyprasert, W.
    Sasanakul, W.
    HAEMOPHILIA, 2013, 19 (03) : E182 - E183
  • [30] Interdisciplinary management of total knee replacement in a haemophilia patient with high-titre inhibitor and severe arthropathy complicated by an aneurysmatic bone cyst
    Ilg, A.
    Stahlschmidt, K.
    Zotz, R. B.
    Krauspe, R.
    Scharf, R. E.
    Gerhardt, A.
    HAEMOPHILIA, 2009, 15 (01) : 377 - 379
12345